Thinking of joining a study?

Register your interest

NCT05692882 | Not yet recruiting | Intracranial Arteriosclerosis


A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China
Sponsor:

Sinomed Neurovita Technology Inc.

Brief Summary:

The primary objective of this trial is to evaluate the long-term safety and efficacy of the NOVA intracranial drug-eluting stent system in "real world" patients with intracranial atherosclerotic stenosis.

Condition or disease

Intracranial Arteriosclerosis

Stenosis Artery

Drug-Eluting Stents

Intracranial Artery Stenosis

Intervention/treatment

Drug-Eluting Stents

Phase

Not Applicable

Detailed Description:

The investigation is a prospective, multi-center, single arm clinical study. The trial is anticipated to last from December 2022 to December 2030 with 1000 subjects recruited in around 50 Chinese centers. The population for this study is subjects with intracranial atherosclerotic stenosis who are suitable candidates for stent angioplasty. Patients fulfilling all of the inclusion criteria and none of the exclusion criteria will be enrolled after they signed the informed consent form. The study consists of ten visits including preoperative screening, operation date, 30 days, 3, 6 months, 1, 2, 3, 4 years and 5 years. The primary outcome was a composite of stroke or death within 30 days or any ischemic stroke or revascularization from the original culprit intracranial artery beyond 30 days through 12 months after operation.

Study Type : Interventional
Estimated Enrollment : 1000 participants
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: To Evaluate the Safety and Efficacy of the NOVA Intracranial Drug-eluting Stent System in "Real World" Patients With Intracranial Atherosclerotic Stenosis: A Prospective, Multicenter, Post-marketing Registry Clinical Study (NOVA II)
Actual Study Start Date : April 1, 2023
Estimated Primary Completion Date : December 30, 2025
Estimated Study Completion Date : December 30, 2029
Arm Intervention/treatment

Experimental: Percutaneous transluminal angioplasty and stenting

All patients will be implanted with Drug-Eluting Stents (NOVA DES).

Device: Drug-Eluting Stents

Ages Eligible for Study: 18 Years to 85 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Criteria
Inclusion Criteria
  • Males or females between 18 and 80 years of age;
  • Symptomatic intracranial arteriosclerosis stenosis with reference diameter 2.25-4.00mm;
  • intracranial artery stenosis ( ≥70%) conformed by digital subtraction angiography (DSA);
  • Those who voluntarily participate in the study and sign informed consent form.
Exclusion Criteria
  • Those who have surgery within previous 30 days or plan to perform major surgery in the next 90 days (surgery grade 3 and above);
  • Subjects of acute hemorrhagic stroke within 3 months;
  • The baseline mRS of disabling stroke is more than 3;
  • The target vessel is severely calcified and closely related to stenosis;
  • Non-atherosclerotic diseases (e.g. arterial dissection, Moya Moya disease, vascular inflammatory lesions caused by infection, autoimmune diseases, post-irradiation, postpartum status; developmental or genetic abnormalities such as fibromuscular dysplasia, sickle cell anemia, suspected vasospasm);
  • It is suspected that the ischemic event is due to embolism or arterial embolism from the extracranial segment (including ipsilateral chest or neck vascular occlusive disease) or potential cardiogenic embolism (e.g. atrial fibrillation, mitral stenosis, patent foramen ovale, left ventricular thrombus, myocardial infarction within 6 weeks, etc.);
  • Target artery's supplying artery stenosis > 50%. For example, patient with middle cerebral artery (MCA) severe stenosis (target artery) and the ipsilateral internal carotid artery (ICA) stenosis > 50% should be excluded; patient with basilar artery (BA) severe stenosis (target artery) and the dominant vertical artery (VA) stenosis > 50% should be excluded;
  • There are intracranial tumors, or intracranial arteriovenous malformations;
  • Those who are allergic to heparin, aspirin, clopidogrel, contrast agents, anesthetics, and stent components;
  • Pregnant and lactating women
  • Those who are unable to complete follow-up because of mental illness, cognitive or emotional disorders;
  • Inapplicable for this study at the investigators' viewpoints.

A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China

Location Details


Please Choose a site



A Registry Study of Intracranial Atherosclerotic Stenosis Treatment by Intracranial Drug-eluting Stenting in China

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations


Loading...